Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie is transitioning immunology sales to new and more effective treatments, ... (up 24%) continues to benefit from label expansion into major depression.

AbbVie (NYSE: ABBV) recently announced that its immunology drug Rinvoq had received approval from the European Commission (EC) to treat adolescent and adult patients with moderate-to-severe atopic ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie plans to release Q4 2024 results on Jan. 31. ... AbbVie Builds Momentum With Immunology Growth, ... with double-digit expansion of 10-11% expected in 2026 and 2027.

CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total net revenues for the year, up 4.6% operationally, despite $5 billion in ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn. The agreement will give AbbVie access to Capstan’s lead CAR-T therapy ...

Wells Fargo analyst Mohit Bansal has maintained their bullish stance on ABBV stock, giving a Buy rating today. Mohit Bansal has given his Buy rating due to a combination of factors that enhance ...

AbbVie successfully licensed its first TriNKET™ drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019, in January 2021. Jonathon Sedgwick, Vice President ...

Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.